SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) announced that CEO Marco Taglietti will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami. The presentation will take place on May 25, 2022, from 11 a.m. to 11:30 a.m. EDT at Fontainebleau Miami Beach Hotel. SCYNEXIS is a biotechnology company focused on developing innovative treatments for difficult-to-treat and drug-resistant infections. Their lead product, BREXAFEMME^® (ibrexafungerp), received FDA approval on June 1, 2021. For more information, visit their website.

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.

SCYNEXIS Presentation details:

H.C. Wainwright Global Investment Conference
Location: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Fla.
Format: In person presentation and 1-on-1 meetings
Date: Wednesday, May 25, 2022
Time: 11 a.m. – 11:30 a.m. EDT

For more information click here.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets), approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, clinical investigation and development of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information visit www.scynexis.com. 

CONTACT: 

Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Brett Whelan
LifeSci Communications
Tel: (339) 368-0466
bwhelan@lifescicomms.com

FAQ

What is SCYNEXIS presenting at the H.C. Wainwright Global Investment Conference?

SCYNEXIS will present its innovative treatments for drug-resistant infections, including updates on its lead product, ibrexafungerp.

When is Marco Taglietti's presentation scheduled?

Marco Taglietti's presentation is scheduled for May 25, 2022, from 11 a.m. to 11:30 a.m. EDT.

Where will the H.C. Wainwright Global Investment Conference be held?

The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, Florida.

What is the stock symbol for SCYNEXIS?

The stock symbol for SCYNEXIS is SCYX.

What recent product did SCYNEXIS launch?

SCYNEXIS launched BREXAFEMME^® (ibrexafungerp tablets), approved by the FDA on June 1, 2021.